Sanofi to buy U.S. haemophilia group Bioverativ for $11.6 billion

PARIS (Reuters) – French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion, in a deal which it said would

Read Original Article: